Erlotinib in the treatment of advanced squamous cell NSCLC
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00069219" target="_blank" >RIV/00216224:14110/13:00069219 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/13:43907525 RIV/00216208:11150/13:10140105 RIV/00179906:_____/13:10140105 RIV/00669806:_____/13:10140105 and 2 more
Result on the web
<a href="http://dx.doi.org/10.4149/neo_2013_086" target="_blank" >http://dx.doi.org/10.4149/neo_2013_086</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/neo_2013_086" target="_blank" >10.4149/neo_2013_086</a>
Alternative languages
Result language
angličtina
Original language name
Erlotinib in the treatment of advanced squamous cell NSCLC
Original language description
Erlotinib is an epidermal growth factor receptor tyrosine-kinase inhibitor. Clinical trials have shown its efficacy in advanced non-small cell lung cancer (NSCLC). We conducted a large retrospective study based on clinical experience aiming to prove erlotinib?s efficacy and safety in patients with advanced-stage squamous cell NSCLC. Totally 375 patients with advanced-stage(IIIB, IV) squamous cell NSCLC were treated with erlotinib. Erlotinib was continued until disease progression or intolerable toxicity. 1 (0.3%) complete response (CR), 28 (7.5%) partial responses (PR) and 198 (52.8%) stable diseases (SD) were achieved. Overall response rate (ORR) and disease control rate (DCR) were 7.8% and 60.5%, respectively. Median progression-free survival (PFS) was 3.0 months and median overall survival (OS) was 7.6 months. PFS of patients with CR/PR, SD and PD were 7.6, 3.9 and 1.0 months, respectively (P<0.001). OS of patients with CR/PR, SD and PD were 13.3, 10.9 and 3.8 months, respectivel
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FC - Pneumology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NR9087" target="_blank" >NR9087: Use of molecular predictors for optimum selection of targeted therapy of non-small cell lung cancer</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Neoplasma
ISSN
0028-2685
e-ISSN
—
Volume of the periodical
60
Issue of the periodical within the volume
6
Country of publishing house
SK - SLOVAKIA
Number of pages
7
Pages from-to
676-682
UT code for WoS article
000325039800011
EID of the result in the Scopus database
—